chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Product dose omission issue
Clinical narrative: joint pain on the legs; Missed dose; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Missed dose) and ARTHRALGIA (joint pain on the legs) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 044A21A) for COVID-19 vaccination.     Concomitant products included ACETAMINOPHEN for Joint pain, GABAPENTIN, METOPROLOL, HYDROCHLOROTHIAZIDE, LISINOPRIL (LISINOPRIL + HIDROCLOROTIAZIDA), NABUMETONE and VITAMIN E NOS for an unknown indication.    On 10-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-Apr-2021, the patient experienced PRODUCT DOSE OMISSION ISSUE (Missed dose). On an unknown date, the patient experienced ARTHRALGIA (joint pain on the legs). At the time of the report, PRODUCT DOSE OMISSION ISSUE (Missed dose) had resolved and ARTHRALGIA (joint pain on the legs) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: sore arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (sore arm) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 018B21A) for COVID-19 vaccination.     Concurrent medical conditions included Diabetes. Concomitant products included INSULIN GLARGINE (LANTUS) and INSULIN LISPRO (HUMALOG) for Diabetes, IRBESARTAN (AVAPRO) and LEVOTHYROXINE SODIUM (SYNTHROID) for an unknown indication.    On 04-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (sore arm). The patient was treated with AMOXICILLIN at a dose of 1 dosage form and CODEINE at a dose of 1 dosage form. At the time of the report, PAIN IN EXTREMITY (sore arm) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       This case was linked to MOD-2021-067216, MOD-2021-067216 (Patient Link).
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Pain in extremity
Clinical narrative: sore arm; headache; This spontaneous case was reported by an other health care professional and describes the occurrence of PAIN IN EXTREMITY (sore arm) and HEADACHE (headache) in a 33-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 001C21A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included OXYMETAZOLINE HYDROCHLORIDE (CLARITIN ALLERGIC) for an unknown indication.    On 14-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Apr-2021, the patient experienced PAIN IN EXTREMITY (sore arm) and HEADACHE (headache). The patient was treated with PARACETAMOL (TYLENOL) ongoing since an unknown date at a dose of 1 dosage form. On 17-Apr-2021, PAIN IN EXTREMITY (sore arm) and HEADACHE (headache) had resolved. Not Provided      mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   This case was linked to MOD-2021-132192 (Patient Link).
Age: 66.0
Sex: M
Vaccine: COVID19
Symptoms: Heart rate increased, Inappropriate schedule of product administration
Clinical narrative: Inappropriate schedule of vaccine administered; This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Inappropriate schedule of vaccine administered) in a 66-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 17-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 21-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form(s). On 21-May-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Inappropriate schedule of vaccine administered). On 21-May-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Inappropriate schedule of vaccine administered) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Heart rate increased: unknown (High) rapid heartbeat.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route), the reporter did not provide any causality assessments.   No Concomitant  and Treatment medications was reported.   Most recent FOLLOW-UP information incorporated above includes: On 14-Jun-2021: Follow-up received start date of the suspect
Age: 83.0
Sex: F
Vaccine: COVID19
Symptoms: Discomfort, Headache, Myalgia, Nasopharyngitis
Clinical narrative: Body feels heavy; Feels as if cold is coming; Aching; Headache; This spontaneous case was reported by a consumer and describes the occurrence of DISCOMFORT (Body feels heavy), NASOPHARYNGITIS (Feels as if cold is coming), HEADACHE (Headache) and MYALGIA (Aching) in an 83-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 12-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-May-2021, the patient experienced HEADACHE (Headache). On 13-May-2021, the patient experienced DISCOMFORT (Body feels heavy), NASOPHARYNGITIS (Feels as if cold is coming) and MYALGIA (Aching). At the time of the report, DISCOMFORT (Body feels heavy), NASOPHARYNGITIS (Feels as if cold is coming), HEADACHE (Headache) and MYALGIA (Aching) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported  No treatment drugs were reported
Sex: M
Vaccine: COVID19
Symptoms: Adverse reaction, Anxiety, Chills, Fatigue, Heart rate increased
Clinical narrative: Anxiety attack; Normal temporary side effects; Rapid heart beat; Sweating; Chills; Fatigue; This spontaneous case was reported by a patient (subsequently medically confirmed) and describes the occurrence of HEART RATE INCREASED (Rapid heart beat), HYPERHIDROSIS (Sweating), ANXIETY (Anxiety attack), ADVERSE REACTION (Normal temporary side effects) and CHILLS (Chills) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Weight loss. Concurrent medical conditions included Blood pressure high and Anxiety disorder. Concomitant products included BUSPIRONE for Anxiety disorder, METOPROLOL for Blood pressure high.   On 15-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 13-May-2021, the patient experienced HYPERHIDROSIS (Sweating), CHILLS (Chills) and FATIGUE (Fatigue). On 14-May-2021, the patient experienced HEART RATE INCREASED (Rapid heart beat). On an unknown date, the patient experienced ANXIETY (Anxiety attack) and ADVERSE REACTION (Normal temporary side effects). At the time of the report, HEART RATE INCREASED (Rapid heart beat), HYPERHIDROSIS (Sweating), ANXIETY (Anxiety attack), ADVERSE REACTION (Normal temporary side effects), CHILLS (Chills) and FATIGUE (Fatigue) outcome was unknown.            The patient reported receiving the Moderna vaccine series (exact date of second dose not provided) and experienced adverse events with symptoms of rapid heart beat, chills, sweating, and fatigue. He reported he would be seeking immediate medical attention and would update Moderna following his hospital visit. Treatment information was not reported.  Action taken with mRNA-1273 in response to the event was not applicable.   Most recent FOLLOW-UP information incorporated above includes: On 18-Jun-2021: Significant follow up
Sex: M
Vaccine: COVID19
Symptoms: Hyperhidrosis
Clinical narrative: Anxiety attack; Normal temporary side effects; Rapid heart beat; Sweating; Chills; Fatigue; This spontaneous case was reported by a patient (subsequently medically confirmed) and describes the occurrence of HEART RATE INCREASED (Rapid heart beat), HYPERHIDROSIS (Sweating), ANXIETY (Anxiety attack), ADVERSE REACTION (Normal temporary side effects) and CHILLS (Chills) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Weight loss. Concurrent medical conditions included Blood pressure high and Anxiety disorder. Concomitant products included BUSPIRONE for Anxiety disorder, METOPROLOL for Blood pressure high.   On 15-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 13-May-2021, the patient experienced HYPERHIDROSIS (Sweating), CHILLS (Chills) and FATIGUE (Fatigue). On 14-May-2021, the patient experienced HEART RATE INCREASED (Rapid heart beat). On an unknown date, the patient experienced ANXIETY (Anxiety attack) and ADVERSE REACTION (Normal temporary side effects). At the time of the report, HEART RATE INCREASED (Rapid heart beat), HYPERHIDROSIS (Sweating), ANXIETY (Anxiety attack), ADVERSE REACTION (Normal temporary side effects), CHILLS (Chills) and FATIGUE (Fatigue) outcome was unknown.            The patient reported receiving the Moderna vaccine series (exact date of second dose not provided) and experienced adverse events with symptoms of rapid heart beat, chills, sweating, and fatigue. He reported he would be seeking immediate medical attention and would update Moderna following his hospital visit. Treatment information was not reported.  Action taken with mRNA-1273 in response to the event was not applicable.   Most recent FOLLOW-UP information incorporated above includes: On 18-Jun-2021: Significant follow up
Age: 58.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Night sweats
Clinical narrative: Nighttime joint pain; Night sweating; This spontaneous case was reported by a consumer and describes the occurrence of ARTHRALGIA (Nighttime joint pain) and NIGHT SWEATS (Night sweating) in a 58-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 038A21A and 036321A) for COVID-19 vaccination.     The patient's past medical history included No adverse event.   On 20-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 17-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 18-Apr-2021, the patient experienced ARTHRALGIA (Nighttime joint pain) and NIGHT SWEATS (Night sweating). At the time of the report, ARTHRALGIA (Nighttime joint pain) and NIGHT SWEATS (Night sweating) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.
Sex: M
Vaccine: COVID19
Symptoms: Product dose omission issue
Clinical narrative: Missed the 2nd dose of Moderna vaccine; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Missed the 2nd dose of Moderna vaccine) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (Missed the 2nd dose of Moderna vaccine). At the time of the report, PRODUCT DOSE OMISSION ISSUE (Missed the 2nd dose of Moderna vaccine) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Relevant concomitant product usage were not reported by the reporter. No treatment details were added.
Age: 65.0
Sex: M
Vaccine: COVID19
Symptoms: Device connection issue, Underdose
Clinical narrative: Syringe started leaking about 0.2 - 0.3 ml; Syringe started leaking about 0.2 - 0.3 ml; This spontaneous case was reported by a pharmacist (subsequently medically confirmed) and describes the occurrence of UNDERDOSE (Syringe started leaking about 0.2 - 0.3 ml) and DEVICE CONNECTION ISSUE (Syringe started leaking about 0.2 - 0.3 ml) in a 65-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 035C21A) for COVID-19 vaccination.     The patient's past medical history included No adverse reaction (No medical history reported.).    On 14-May-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-May-2021, the patient experienced UNDERDOSE (Syringe started leaking about 0.2 - 0.3 ml) and DEVICE CONNECTION ISSUE (Syringe started leaking about 0.2 - 0.3 ml). At the time of the report, UNDERDOSE (Syringe started leaking about 0.2 - 0.3 ml) and DEVICE CONNECTION ISSUE (Syringe started leaking about 0.2 - 0.3 ml) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medicines were reported. No treatment information were reported.  Action taken with the drug in response to events was not applicable.
Age: 53.0
Sex: M
Vaccine: COVID19
Symptoms: Herpes zoster
Clinical narrative: shingles on the right lower back down and around to his groin; This spontaneous case was reported by a consumer and describes the occurrence of HERPES ZOSTER (shingles on the right lower back down and around to his groin) in a 53-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039A21A) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 31-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-May-2021, the patient experienced HERPES ZOSTER (shingles on the right lower back down and around to his groin). At the time of the report, HERPES ZOSTER (shingles on the right lower back down and around to his groin) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No Concomitant medication were reported.  No treatment medication were reported.
Age: 14.0
Sex: M
Vaccine: COVID19
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: vaccine given to a 14 year old male; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (vaccine given to a 14 year old male) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 14-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-May-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (vaccine given to a 14 year old male). On 14-May-2021, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (vaccine given to a 14 year old male) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   This case was linked to MODERNATX, INC.-MOD-2021-132265 (E2B Linked Report).; Sender's Comments:  MODERNATX, INC.-MOD-2021-132265:
Sex: M
Vaccine: COVID19
Symptoms: Dyspnoea
Clinical narrative: He is having difficulty breathing; This spontaneous case was reported by a consumer and describes the occurrence of DYSPNEA (He is having difficulty breathing) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced DYSPNEA (He is having difficulty breathing). At the time of the report, DYSPNEA (He is having difficulty breathing) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment medication was not provided   Most recent FOLLOW-UP information incorporated above includes: On 15-Jun-2021: Non-significant follow-up added to include AE contact info
Age: 18.0
Sex: M
Vaccine: COVID19
Symptoms: Rash
Clinical narrative: Allergic reaction like rash and getting like bumps; This spontaneous case was reported by a consumer and describes the occurrence of RASH (Allergic reaction like rash and getting like bumps) in an 18-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027B21A) for COVID-19 vaccination.     No Medical History information was reported.   On 14-May-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 14-May-2021, the patient experienced RASH (Allergic reaction like rash and getting like bumps). At the time of the report, RASH (Allergic reaction like rash and getting like bumps) outcome was unknown. Not Provided          He was eating shrimp and got allergic reaction on the same day of vaccination. He stated that he was pretty sure that the allergic reaction was from shrimp.  No concomitant medication reported.
Age: 24.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: The patient received the expired vaccine/passed 30 days window period of refrigeration; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (The patient received the expired vaccine/passed 30 days window period of refrigeration) in a 24-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 005C21A and 044A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 14-May-2021 at 9:08 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-Jun-2021 at 9:06 AM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 14-May-2021 at 9:06 AM, the patient experienced EXPIRED PRODUCT ADMINISTERED (The patient received the expired vaccine/passed 30 days window period of refrigeration). On 14-May-2021 at 9:06 AM, EXPIRED PRODUCT ADMINISTERED (The patient received the expired vaccine/passed 30 days window period of refrigeration) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered EXPIRED PRODUCT ADMINISTERED (The patient received the expired vaccine/passed 30 days window period of refrigeration) to be not related.    No concomitant medications provided.  The patient had no side effects or adverse reactions.  No treatment information provided.   Most recent FOLLOW-UP information incorporated above includes: On 15-Jun-2021: Follow-up received updated dose 2 information, action taken, patient details.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Chest pain, Headache, Mass, Nausea, Pyrexia
Clinical narrative: Glands on the left clavicle; Sore chest; Fever; Headache; Nausea; This spontaneous case was reported by a consumer and describes the occurrence of MASS (Glands on the left clavicle), CHEST PAIN (Sore chest), PYREXIA (Fever), HEADACHE (Headache) and NAUSEA (Nausea) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 031B21A and 031B21A) for COVID-19 vaccination.     Concurrent medical conditions included Migraine. Concomitant products included ACETAMINOPHEN for Migraine.   On 14-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 11-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced MASS (Glands on the left clavicle), CHEST PAIN (Sore chest), PYREXIA (Fever), HEADACHE (Headache) and NAUSEA (Nausea). At the time of the report, MASS (Glands on the left clavicle), CHEST PAIN (Sore chest), PYREXIA (Fever), HEADACHE (Headache) and NAUSEA (Nausea) outcome was unknown.        mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Treatment for the events taken with Ibuprofen.
Sex: F
Vaccine: COVID19
Symptoms: Product dose omission issue
Clinical narrative: 44 days has passed from dose 1; This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (44 days has passed from dose 1) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (44 days has passed from dose 1). At the time of the report, PRODUCT DOSE OMISSION ISSUE (44 days has passed from dose 1) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   This case was linked to MOD-2021-133228 (Patient Link).
Age: 21.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Pain in extremity
Clinical narrative: tiredness/fatigue; sore arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (sore arm) and FATIGUE (tiredness/fatigue) in a 21-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 028A21A) for COVID-19 vaccination.     No medical history is reported.  Concomitant products included VITAMIN D NOS for an unknown indication.    On 07-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-Apr-2021, the patient experienced PAIN IN EXTREMITY (sore arm). On 08-Apr-2021, the patient experienced FATIGUE (tiredness/fatigue). On 09-Apr-2021, FATIGUE (tiredness/fatigue) had resolved. On 10-Apr-2021, PAIN IN EXTREMITY (sore arm) had resolved.            Treatment information was not provided, for first dose.   This case was linked to MOD-2021-132189 (Patient Link).
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: This spontaneous case reported by a consumer, describes the occurrence of pain in extremity (sore arm) in a 37-year-old female patient who received mRNA-1273 (Moderna COVID-19 vaccine, batch# 026L20A) for COVID-19 immunization. No medical history provided. Concomitant products included Lexapro and Wellbutrin. On Jan 8, 2021, patient received the first dose of mRNA-1273 (Moderna COVID-19 vaccine), intramuscular; 1 dosage form. On Jan 8, 2021, patient experienced pain in extremity (sore arm). At the time of the report, pain in extremity (sore arm) outcome: unknown/not provided. The action taken with mRNA-1273 (Moderna COVID-19 vaccine), intramuscular: unknown. The reporter did not provide any causality assessments. This case linked to MOD-2021-132216 (patient link).
Sex: M
Vaccine: COVID19
Symptoms: Fatigue, Headache, Pain
Clinical narrative: headaches; Body aches; Tiredness; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (Body aches), FATIGUE (Tiredness) and HEADACHE (headaches) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 014C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 24-Apr-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. On 24-Apr-2021, the patient experienced PAIN (Body aches) and FATIGUE (Tiredness). On an unknown date, the patient experienced HEADACHE (headaches). At the time of the report, PAIN (Body aches), FATIGUE (Tiredness) and HEADACHE (headaches) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication details was reported. No treatment medication was provided.    This case was linked to MOD21-090747, US-MODERNATX, INC.-MOD-2021-133325 (E2B Linked Report).; Sender's Comments:  MOD21-090747: US-MODERNATX, INC.-MOD-2021-133325:son case
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Myalgia, Vomiting
Clinical narrative: Vomiting nonstop for 7 hours straight; Chills; Body aches; This spontaneous case was reported by a patient and describes the occurrence of VOMITING (Vomiting nonstop for 7 hours straight), CHILLS (Chills) and MYALGIA (Body aches) in a 25-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. Unknown and 026C27A) for COVID-19 vaccination.     Concurrent medical conditions included Acne. Concomitant products included SPIRONOLACTONE for Acne.   On 15-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 13-May-2021 at 2:55 AM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 13-May-2021, the patient experienced VOMITING (Vomiting nonstop for 7 hours straight) and CHILLS (Chills). 13-May-2021, the patient experienced MYALGIA (Body aches). At the time of the report, VOMITING (Vomiting nonstop for 7 hours straight), CHILLS (Chills) and MYALGIA (Body aches) had not resolved.            treatment for the events included Pepto-Bismol Action taken with mRNA-1273 in response to the events was not Applicable
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Diarrhoea, Dizziness, Insomnia, Malaise
Clinical narrative: This spontaneous case reported by a patient, describes the occurrence of malaise (feeling very ill), pyrexia (fever), myalgia (body ache/achy), insomnia (could not sleep) and dizziness in a female patient, of an unknown age, who received mRNA-1273 (Moderna COVID-19 vaccine, batch# 017C21A) for COVID-19 immunization. The occurrence of additional events detailed below. No medical history reported. On May 4, 2021, patient received the first dose of mRNA-1273 (Moderna COVID-19 vaccine), intramuscular; 1 dosage form. On May 4, 2021, patient experienced insomnia (could not sleep). On May 5, 2021, patient experienced malaise (feeling very ill), pyrexia (fever), myalgia (body ache/achy), dizziness, diarrhea and asthenia (still very weak). On an unknown date, patient had pain in extremity (left arm was very sore). At the time of the report, malaise (feeling very ill), pyrexia (fever), myalgia (body ache/achy), insomnia (could not sleep), dizziness, diarrhea, asthenia (still very weak) and pain in extremity (left arm was very sore) outcome:  unknown. The action taken with mRNA-1273 (Moderna COVID-19 vaccine), intramuscular: unknown. Patient does not want to take her second dose. No concomitant medication or treatment information provided.
Sex: F
Vaccine: COVID19
Symptoms: Myalgia, Pain in extremity, Pyrexia
Clinical narrative: This spontaneous case reported by a patient, describes the occurrence of malaise (feeling very ill), pyrexia (fever), myalgia (body ache/achy), insomnia (could not sleep) and dizziness in a female patient, of an unknown age, who received mRNA-1273 (Moderna COVID-19 vaccine, batch# 017C21A) for COVID-19 immunization. The occurrence of additional events detailed below. No medical history reported. On May 4, 2021, patient received the first dose of mRNA-1273 (Moderna COVID-19 vaccine), intramuscular; 1 dosage form. On May 4, 2021, patient experienced insomnia (could not sleep). On May 5, 2021, patient experienced malaise (feeling very ill), pyrexia (fever), myalgia (body ache/achy), dizziness, diarrhea and asthenia (still very weak). On an unknown date, patient had pain in extremity (left arm was very sore). At the time of the report, malaise (feeling very ill), pyrexia (fever), myalgia (body ache/achy), insomnia (could not sleep), dizziness, diarrhea, asthenia (still very weak) and pain in extremity (left arm was very sore) outcome:  unknown. The action taken with mRNA-1273 (Moderna COVID-19 vaccine), intramuscular: unknown. Patient does not want to take her second dose. No concomitant medication or treatment information provided.
Sex: U
Vaccine: COVID19
Symptoms: Fatigue, Pain in extremity, Palpitations, Tachycardia, Vaccination site erythema
Clinical narrative: tachycardia; palpitations; arm pain; arm has been super irritated in the injection area; pain in the injection area and is inflamed and red; fatigue; pain in the injection area and is inflamed and red; pain in the injection area and is inflamed and red; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of TACHYCARDIA (tachycardia), PALPITATIONS (palpitations), PAIN IN EXTREMITY (arm pain), VACCINATION SITE IRRITATION (arm has been super irritated in the injection area) and VACCINATION SITE INFLAMMATION (pain in the injection area and is inflamed and red) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Pfizer vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced TACHYCARDIA (tachycardia), PALPITATIONS (palpitations), PAIN IN EXTREMITY (arm pain), VACCINATION SITE IRRITATION (arm has been super irritated in the injection area), VACCINATION SITE INFLAMMATION (pain in the injection area and is inflamed and red), FATIGUE (fatigue), VACCINATION SITE PAIN (pain in the injection area and is inflamed and red) and VACCINATION SITE ERYTHEMA (pain in the injection area and is inflamed and red). At the time of the report, TACHYCARDIA (tachycardia), PALPITATIONS (palpitations), PAIN IN EXTREMITY (arm pain), VACCINATION SITE IRRITATION (arm has been super irritated in the injection area), VACCINATION SITE INFLAMMATION (pain in the injection area and is inflamed and red), FATIGUE (fatigue), VACCINATION SITE PAIN (pain in the injection area and is inflamed and red) and VACCINATION SITE ERYTHEMA (pain in the injection area and is inflamed and red) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.  No concomitant medications were reported.   No treatment information was provided.
Sex: U
Vaccine: COVID19
Symptoms: Vaccination site inflammation, Vaccination site irritation, Vaccination site pain
Clinical narrative: tachycardia; palpitations; arm pain; arm has been super irritated in the injection area; pain in the injection area and is inflamed and red; fatigue; pain in the injection area and is inflamed and red; pain in the injection area and is inflamed and red; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of TACHYCARDIA (tachycardia), PALPITATIONS (palpitations), PAIN IN EXTREMITY (arm pain), VACCINATION SITE IRRITATION (arm has been super irritated in the injection area) and VACCINATION SITE INFLAMMATION (pain in the injection area and is inflamed and red) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Pfizer vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced TACHYCARDIA (tachycardia), PALPITATIONS (palpitations), PAIN IN EXTREMITY (arm pain), VACCINATION SITE IRRITATION (arm has been super irritated in the injection area), VACCINATION SITE INFLAMMATION (pain in the injection area and is inflamed and red), FATIGUE (fatigue), VACCINATION SITE PAIN (pain in the injection area and is inflamed and red) and VACCINATION SITE ERYTHEMA (pain in the injection area and is inflamed and red). At the time of the report, TACHYCARDIA (tachycardia), PALPITATIONS (palpitations), PAIN IN EXTREMITY (arm pain), VACCINATION SITE IRRITATION (arm has been super irritated in the injection area), VACCINATION SITE INFLAMMATION (pain in the injection area and is inflamed and red), FATIGUE (fatigue), VACCINATION SITE PAIN (pain in the injection area and is inflamed and red) and VACCINATION SITE ERYTHEMA (pain in the injection area and is inflamed and red) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.  No concomitant medications were reported.   No treatment information was provided.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Dysgeusia, Parosmia, Product dose omission issue
Clinical narrative: due to personal issues she could not get the 2nd dose within the dosing window; Metallic taste of vaccine; Metallic smell of vaccine; This spontaneous case was reported by a patient and describes the occurrence of DYSGEUSIA (Metallic taste of vaccine), PAROSMIA (Metallic smell of vaccine) and PRODUCT DOSE OMISSION ISSUE (due to personal issues she could not get the 2nd dose within the dosing window) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 044A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 30-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) at an unspecified dose. On 30-Mar-2021, the patient experienced DYSGEUSIA (Metallic taste of vaccine) and PAROSMIA (Metallic smell of vaccine). On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (due to personal issues she could not get the 2nd dose within the dosing window). At the time of the report, DYSGEUSIA (Metallic taste of vaccine), PAROSMIA (Metallic smell of vaccine) and PRODUCT DOSE OMISSION ISSUE (due to personal issues she could not get the 2nd dose within the dosing window) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Maternal exposure during pregnancy, Myalgia, Vaccination site erythema
Clinical narrative: warmth at injection site; Maternal exposure during pregnancy; raised bumps at injection site; tenderness at injection site; redness at injection site; fatigue/tiredness; body aches; headache; This spontaneous prospective pregnancy case was reported by an other health care professional and describes the occurrence of VACCINATION SITE WARMTH (warmth at injection site), MATERNAL EXPOSURE DURING PREGNANCY (Maternal exposure during pregnancy), VACCINATION SITE SWELLING (raised bumps at injection site), VACCINATION SITE PAIN (tenderness at injection site) and VACCINATION SITE ERYTHEMA (redness at injection site) in a 33-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 035C21A and 001C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was provided by the reporter.  Concomitant products included OXYMETAZOLINE HYDROCHLORIDE (CLARITIN ALLERGIC) for an unknown indication.   On 14-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 13-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. The patient's last menstrual period was on 06-Apr-2021 and the estimated date of delivery was 11-Jan-2022. On 14-Apr-2021, the patient experienced HEADACHE (headache). On 13-May-2021, the patient experienced VACCINATION SITE WARMTH (warmth at injection site), MATERNAL EXPOSURE DURING PREGNANCY (Maternal exposure during pregnancy), VACCINATION SITE SWELLING (raised bumps at injection site), VACCINATION SITE PAIN (tenderness at injection site), VACCINATION SITE ERYTHEMA (redness at injection site), FATIGUE (fatigue/tiredness) and MYALGIA (body aches). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  fifth week of the pregnancy.  On 17-Apr-2021, HEADACHE (headache) had resolved. On 13-May-2021, MATERNAL EXPOSURE DURING PREGNANCY (Maternal exposure during pregnancy) had resolved. At the time of the report, VACCINATION SITE WARMTH (warmth at injection site), VACCINATION SITE SWELLING (raised bumps at injection site), VACCINATION SITE PAIN (tenderness at injection site), VACCINATION SITE ERYTHEMA (redness at injection site), FATIGUE (fatigue/tiredness) and MYALGIA (body aches) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Patient received the first dose was before she was pregnant and the second dose was when she was 5 weeks pregnant. Her last menstrual was 06-Apr-2021.   This case was linked to MOD-2021-132161 (Patient Link).
Age: 33.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain, Vaccination site swelling, Vaccination site warmth
Clinical narrative: warmth at injection site; Maternal exposure during pregnancy; raised bumps at injection site; tenderness at injection site; redness at injection site; fatigue/tiredness; body aches; headache; This spontaneous prospective pregnancy case was reported by an other health care professional and describes the occurrence of VACCINATION SITE WARMTH (warmth at injection site), MATERNAL EXPOSURE DURING PREGNANCY (Maternal exposure during pregnancy), VACCINATION SITE SWELLING (raised bumps at injection site), VACCINATION SITE PAIN (tenderness at injection site) and VACCINATION SITE ERYTHEMA (redness at injection site) in a 33-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 035C21A and 001C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was provided by the reporter.  Concomitant products included OXYMETAZOLINE HYDROCHLORIDE (CLARITIN ALLERGIC) for an unknown indication.   On 14-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 13-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. The patient's last menstrual period was on 06-Apr-2021 and the estimated date of delivery was 11-Jan-2022. On 14-Apr-2021, the patient experienced HEADACHE (headache). On 13-May-2021, the patient experienced VACCINATION SITE WARMTH (warmth at injection site), MATERNAL EXPOSURE DURING PREGNANCY (Maternal exposure during pregnancy), VACCINATION SITE SWELLING (raised bumps at injection site), VACCINATION SITE PAIN (tenderness at injection site), VACCINATION SITE ERYTHEMA (redness at injection site), FATIGUE (fatigue/tiredness) and MYALGIA (body aches). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  fifth week of the pregnancy.  On 17-Apr-2021, HEADACHE (headache) had resolved. On 13-May-2021, MATERNAL EXPOSURE DURING PREGNANCY (Maternal exposure during pregnancy) had resolved. At the time of the report, VACCINATION SITE WARMTH (warmth at injection site), VACCINATION SITE SWELLING (raised bumps at injection site), VACCINATION SITE PAIN (tenderness at injection site), VACCINATION SITE ERYTHEMA (redness at injection site), FATIGUE (fatigue/tiredness) and MYALGIA (body aches) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Patient received the first dose was before she was pregnant and the second dose was when she was 5 weeks pregnant. Her last menstrual was 06-Apr-2021.   This case was linked to MOD-2021-132161 (Patient Link).
Sex: M
Vaccine: COVID19
Symptoms: Fatigue, Trigeminal neuralgia
Clinical narrative: Trigeminol Neurlagia; Sever Fatigue; This spontaneous case was reported by a consumer and describes the occurrence of TRIGEMINAL NEURALGIA (Trigeminol Neurlagia) and FATIGUE (Sever Fatigue) in a 55-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 048AZ1A and 040B21A) for COVID-19 immunisation.     Concomitant products included LISINOPRIL, HYDROCHLOROTHIAZIDE, AMLODIPINE, CITALOPRAM, ROSUVASTATIN, PIOGLITAZONE and DULAGLUTIDE (TRULICITY).   On 18-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 18-Mar-2021, the patient experienced TRIGEMINAL NEURALGIA (Trigeminol Neurlagia) and FATIGUE (Sever Fatigue). The patient was treated with CARBAMAZEPINE (TEGRETOL) for Trigeminal neuralgia, at a dose of times daily for five days and OXCARBAZEPINE for Trigeminal neuralgia, at a dose of 150mg three times daily. On 19-Mar-2021, FATIGUE (Sever Fatigue) had resolved. At the time of the report, TRIGEMINAL NEURALGIA (Trigeminol Neurlagia) had resolved.            concomitant medications include Treatment medications were not provided.
Age: 55.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: He received a phone call from vaccine facility next day that the vaccine of 2nd dose was expired.; This spontaneous case was reported by a consumer and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (He received a phone call from vaccine facility next day that the vaccine of 2nd dose was expired.) in a 55-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 004C21A and 031B21A) for COVID-19 vaccination.     No Medical History information was reported.   On 13-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. On 12-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 13-May-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (He received a phone call from vaccine facility next day that the vaccine of 2nd dose was expired.). On 13-May-2021, EXPIRED PRODUCT ADMINISTERED (He received a phone call from vaccine facility next day that the vaccine of 2nd dose was expired.) had resolved.            oncomitant product use was not provided by the reporter. Treatment information was not provided.   This case was linked to US-MODERNATX, INC.-MOD-2021-132200 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-132200:
Age: 76.0
Sex: F
Vaccine: COVID19
Symptoms: Interchange of vaccine products
Clinical narrative: This spontaneous case reported by an other healthcare professional, describes the occurrence of interchange of vaccine products (patient received Pfizer as first dose and Moderna as second dose) in a 76-year-old female patient who received mRNA-1273 (Moderna COVID-19 vaccine) for COVID-19 immunization. Previously administered products included for COVID-19 vaccination: Pfizer. On an unknown date, patient received the second dose of mRNA-1273 (Moderna COVID-19 vaccine), unknown route; 1 dosage form. On an unknown date, patient received the first dose of BNT162B2 (Pfizer-BioNTech COVID-19 vaccine), unknown route; 1 dosage form. On an unknown date, patient experienced interchange of vaccine products (patient received Pfizer as first dose and Moderna as second dose). At the time of the report, interchange of vaccine products (patient received Pfizer as first dose and Moderna as second dose) outcome: unknown. No concomitant medication or treatment information provided.
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: Headache, Muscle spasms
Clinical narrative: Cramps in neck every now and then; Headache when laying down; This spontaneous case was reported by a consumer and describes the occurrence of MUSCLE SPASMS (Cramps in neck every now and then) and HEADACHE (Headache when laying down) in a 67-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 039B21A and 011A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 04-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 12-Apr-2021, the patient experienced MUSCLE SPASMS (Cramps in neck every now and then) and HEADACHE (Headache when laying down). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, MUSCLE SPASMS (Cramps in neck every now and then) and HEADACHE (Headache when laying down) outcome was unknown.            No concomitant medications were mentioned. Treatment medications includes Pain medication along with above mentioned medications.   This case was linked to MOD-2021-139495 (Patient Link).
Age: 21.0
Sex: M
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration
Clinical narrative: Second dose scheduled 22 days after first dose; This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Second dose scheduled 22 days after first dose) in a 21-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 048B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 22-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-May-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Second dose scheduled 22 days after first dose). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Second dose scheduled 22 days after first dose) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were provided by the reporter.  Treatment information was not provided.